Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Core Viewpoint - Stoke Therapeutics has initiated the Phase 1 OSPREY study for STK-002, targeting Autosomal Dominant Optic Atrophy (ADOA), a rare genetic condition leading to vision loss [1] Company Summary - Stoke Therapeutics is focused on restoring protein expression through RNA medicine [1] - The company has announced the dosing of the first patient in its clinical trial for STK-002 [1] Industry Summary - ADOA is characterized as a rare genetic disease that results in progressive and irreversible vision loss, typically beginning in early childhood [1]